Biotest

Biotest Net Debt per Share

Delisted

The Net Debt per Share of Biotest (BIO.DE) as of Nov 22, 2026 is 13.94 EUR. In the previous year, Net Debt per Share was 14.43 EUR — a change of -3.45% (lower).

Net Debt per Share

13.94EUR

YoY

-3.45%

Last updated:

Net Debt per Share of Biotest is 2024 13.94 EUR. Net Debt per Share of Biotest was 2023 14.43 EUR. It decreases by -3.45% lower compared to the previous year.

The Biotest Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
9.56 EUR
Jan 1, 2018
5.64 EUR
Jan 1, 2019
8.19 EUR
Jan 1, 2020
9.60 EUR
Jan 1, 2021
10.41 EUR
Jan 1, 2022
12.82 EUR
Jan 1, 2023
14.43 EUR
Jan 1, 2024
13.94 EUR
The Biotest Net Debt per Share history
YEARNet Debt per ShareYoY
13.94EUR-3.45%
14.43EUR+12.60%
12.82EUR+23.10%
10.41EUR+8.48%
9.60EUR+17.29%
8.19EUR+45.05%
5.64EUR-40.96%
9.56EUR+43.64%
6.65EUR+37.93%
4.82EUR+95.19%
2.47EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

Net Debt per Share of Biotest is 13.94 EUR in 2024.

Net Debt per Share of Biotest changed from 14.43 EUR to 13.94 EUR, representing a -3.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Biotest since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Biotest

All Key Metrics — Biotest